Mesothelioma is a global problem, largely related to the previous use of asbestos products. Diagnosis is very difficult because of its diverse appearances and the potential for other diseases to mimic it. Written by experienced international experts to aid in pathological diagnosis, this book deals with clinical, radiological, epidemiological, molecular, and histopathological aspects of the disease. Tumors of the pleural, pericardial, peritoneal cavities as well as the ovary and tunica vaginalis are considered. Differential diagnoses of serosal-based lesions are discussed and the use of immunohistochemical stains is explained. Plentiful illustrations give further aid to diagnosis.An essential read for all diagnostic pathologists as well as general pathologists, who are sometimes required to diagnose the disease at biopsy or post mortem; also invaluable to medical and legal professions involved with various aspects of the disease.

The ?eld of cellular responses to DNA damage has attained widespread recognition and interest in recent years commensurate with its fundamental role in the ma- tenance of genomic stability. These responses, which are essential to preventing cellular death or malignant transformation, are organized into a sophisticated s- tem designated the "DNA damage response". This system operates in all living organisms to maintain genomic stability in the face of constant attacks on the DNA from a variety of endogenous by-products of normal metabolism, as well as exogenous agents such as radiation and toxic chemicals in the environment. The response repairs DNA damage via an intricate cellular signal transduction network that coordinates with various processes such as regulation of DNA replication, tr- scriptional responses, and temporary cell cycle arrest to allow the repair to take place. Defects in this system result in severe genetic disorders involving tissue degeneration, sensitivity to speci?c damaging agents, immunode?ciency, genomic instability, cancer predisposition and premature aging. The ?nding that many of the crucial players involved in DNA damage response are structurally and functionally conserved in different species spurred discoveries of new players through similar analyses in yeast and mammals. We now understand the chain of events that leads to instantaneous activation of the massive cellular responses to DNA lesions. This book summarizes several new concepts in this rapidly evolving ?eld, and the advances in our understanding of the complex network of processes that respond to DNA damage.

Meaning-Centered-Psychotherapy in the Cancer Setting provides a theoretical context for Meaning-Centered Psychotherapy (MCP), a non-pharmalogic intervention which has been shown to enhance meaning and spiritual well-being, increase hope, improve quality of life, and significantly decrease depression, anxiety, desire for hastened death, and symptom burden distress in the cancer setting. Based on the work of Viktor Frankl and his concept of logotherapy, MCP is an innovative intervention for clinicians practicing in fields of Psycho-oncology, Palliative Care, bereavement, and cancer survivorship. This volume supplements two treatment manuals, Meaning-Centered Group Psychotherapy (MCGP) for Patients with Advanced Cancer and Individual Meaning -Centered Psychotherapy (IMCP) for Patients with Advanced Cancer by Dr. Breitbart, which offer a step-wise outline to conducting a specific set of therapy sessions. In addition to providing a theoretical background on the MCP techniques provided in the treatment manuals, this volume contains chapters on adapting MCP for different cancer-related populations and for different purposes and clinical problems including: interventions for cancer survivors, caregivers of cancer patients, adolescents and young adults with cancer, as a bereavement intervention, and cultural and linguistic applications in languages such as Mandarin, Spanish, and Hebrew.

The aim of this book will be to contribute to the education of a new generation of experts in urology, molecular biology, pathology and oncology, offering them sufficient knowledge in basic and translational research to be fluency in the web of interacting networks playing a role in prostate cancer development, progression, metastasis and drug-resistance.The volume will cover the latest innovative researches in prostate cancer, with particular emphasis to the state-of-the-art analysis technologies that are essential for the accurate identification of molecular targets for disease diagnosis, molecular mechanisms of tumorigenesis, markers for susceptibility, molecular-based prognostic prevision, characterization of biomarkers of drug efficacy and drug resistance, validation of new therapeutics and diagnostics. Current advancements on the intersecting data concerning transcriptomes, proteomes, the molecular techniques referred as "omes," will be reported and discussed.

This is a practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs. It includes coverage of basic biostatistics for the clinical trialist, and fundamental concepts in clinical pharmacology.

Much of organic chemistry is based on the ability of suitably structured chemicals to bind together through the formation of covalent bonds. Biochemistry is replete with exam ples of enzymatically catalyzed reactions in which normal body constituents can be linked through covalent bonds during the process of intermediary metabolism. The finding that xenobiotic chemicals that enter the body from the environment, are metabolized to highly reactive species, and then covalently react with cellular macromolecules to induce toxic and carcinogenic effects was an observation that spawned the research featured in the Fifth International Symposium on Biological Reactive Intermediates (BRI V). The group of investigators that became fascinated with this process and its signifi cance in terms of human health began their discussions in Turku, Finland (J 975), and continued them at Guildford, England (1980), College Park, Maryland (1985), Tucson, Arizona (1990), and Munich, Germany (1995). Among the results were a series of reports listed below, as well as the book for which this serves as the Preface. * Jollow, DJ., Kocsis, J.J., Snyder, R. and Vainio, H. (eds), Biological Reactive Intermediates: Formation, Toxicity and Inactivation, Plenum Press, NY, 1975. * Snyder, R., Park, D.V., Kocsis, J.J., Jollow, D.V., Gibson, G.G. and Witmer, C.M. (eds), Biological Reactive Intermediates II: Chemical Mechanisms and Biological Effects, Plenum Press, N.Y., 1982.

Biological inorganic chemistry is a field of research at the interface of inorganic and biological chemistry. The rapidly developing insights into the role of metals in biological systems has far-reaching implications not only for biological science but also for related disciplines, ranging from molecular medicine to the environment. In each volume the reader, whether engaged in chemistry, biochemistry, biology or molecular medicine, receives a comprehensive summary and critical overview of a topic of high current interest written by leading international experts.

The series, Hormones in Health and Disease, was launched in 1993 to provide a scientific platform for investigators engaged in research on the biological actions of hormones and to anticipate relevance for their findings in clinical applications. The first volume of the series was dedicated to the discussion and understanding of molecular mechanisms by which steroid hormones influence target cells in normal and pathological conditions. With the diversity of information and the vast amount of literature on steroid hormone physiology, a more thorough treatment of Hormones and Cancer was identified as a timely topic. In this second volume in the series, Dr. Wayne V. Vedeckis has success fully undertaken the monumental task of editing the findings of the leading investigators in hormone and cancer research. Dr. Vedeckis brings to this project two decades of research experience in hormone action; he is actively engaged in elucidating hormone and cancer interrelations. It is a pleasure to welcome him to the series as an editor and congratulate him and all contribu tors in presenting this comprehensive treatise. The 20 chapters include discussions on contemporary topics relating control of cell division and signal transduction to the basic mechanisms of carcinogenesis by cloning patient genes, and recognizing the importance of steroid receptors in treatment protocols of various endocrine abnormalities."

Despite the major developments in the therapeutic armamentarium for the treatment of infection, the morbidity and mortality of this complication remains very high in patients with compromised defences. Cancer and its treatment represents a major predisposing condition to a variety of infections. These adverse events are still with us, in spite of much progress in the therapy of infectious disease, since cancer therapy is becoming more aggressive, yet further lowering the host's capacity to cope with infections. Moreover, the pathogens adapt effectively to drugs, and at a pace that might outrun industry's capability to produce new agents. Finally, new pathogens are appearing as a consequence of both selection and severe immunosuppression. Infection is so common among cancer patients that its diagnosis and management represent a daily challenge to all oncologists, who must continually strive to keep abreast of developments in the area. The present comprehensive review of the most crucial and challenging aspects of the infectious complications in cancer patients will help them to do just that.

A cutting-edge review of how derangements in the hormonal and growth factor mechanisms controlling normal mammary development lead to breast cancer. Drawing on the multidisciplinary expertise of leading authorities, the book highlights the roles of oncogenes and tumor suppressor genes, spelling out the importance of autocrine/paracrine loops (e.g., stromal epithelial interactions) in supporting breast cancer cell proliferation and the progression to hormone independence. The book's many prominent contributors also illuminate significant recent advances in the biochemistry and physiology of hormone receptors and review the state-of -the-art in the endocrine therapy of breast cancer. Endocrinology of Breast Cancer provides a unique integrated overview of the most significant basic and clinical developments concerning the hormonal aspects of breast cancer.

Despite advances in detection and treatment, cancer remains a source of pain and distress to patients and of complex challenges to the loved ones caring for them. The trend toward shorter hospital stays in particular has increased the physical, psychological, and financial burden on caregivers, often leading to adverse effects on patients.

"Cancer Caregiving in the United States" illuminates these complex concerns with authoritative detail. This wide-ranging volume provides a comprehensive survey of cancer-related issues, including those affecting the care triad (patients-family members- professionals) and quality of care as well as the numerous physical, emotional, and financial challenges that caregivers may need to confront. Sources of caregiver difficulty at each stage of the disease, from diagnosis to end of life, are explored. Each chapter analyzes its topic in terms of practice, research, education, and policy, providing a wealth of literature reviews, assessment and care models, interventions, and recommendations for future study and practice.

Coverage includes:

Caregiving issues for cancer patients with long-term, short-term, and intermittent needs.Family caregivers as members of the treatment team.The impact of health disparities on caregivers.Cancer care policy and advocacy.End-of-life issues for cancer caregivers.Legal, financial, and ethical issues.

"Cancer Caregiving in the United States" is a core reference for researchers, professionals/scientist-practitioners, and graduate students in such caregiving fields as clinical psychology, social work, nursing, public health and medicine, social policy, and educational policy."

Newly developed molecular target anticancer drugs have shown remarkable efficacy even in the treatment of intractable cancers such as hepatoma and renal cell carcinoma. As cancer research is becoming a multidisciplinary endeavor, close cooperation across the basic, translational, and clinical research fields holds the promise of further advances in cancer therapeutics. This book sets forth new strategies for development: cancer therapy targeting receptor tyrosine kinases with clinical utilization of new signaling regulations; interaction between cancer progression and extracellular environments such as inflammatory cytokines and the extracellular matrix; and investigation of biomarkers for personalized cancer therapy, with microarray analysis and pharmacogenomics technology. These and other findings from the latest investigations into cancer cell biology and therapeutics make this book an invaluable source for investigators in both the clinical and basic cancer research fields.

This book is about melanoma-its biology, immunology, and pathology, as well as the initial use of powerful genomic tools to study its fundamental mole- lar and genetic characteristics. The study of cancer will be profoundly impacted by the Human Genome Project. I would like to discuss some of these changes. The first draft of the human genome sequence was announced in June 2000, and we have just scratched the surface of the changes it will engender in medicine. A relevant question is what are the long-term effects of the Human Genome Project for medicine? I would argue that there are three, and each of these three point toward the view that systems biology will dominate biology and medicine of the 21st century. First, the Human Genome Project introduced a new type of s- ence-discovery science. Discovery science takes a biological system (e. g. , the genome) and defines all of its elements (e. g. , the sequences of the 24 human ch- mosomes). Thus, it creates a rich infrastructure from which the classical hypo- esis-driven science can be done more effectively. The effective integration of discovery- and hypothesis-driven science is a key for systems approaches to bi- ogy and medicine. Second, the Human Genome Project has provided a "periodic table of life.

In 1890, just a few years after the discovery of the chromosomes, David Paul Hansemann, a pathologist-in-training with the famous Rudolph Virchow in Berlin, produced a theory of the pathogenesis of cancer involving the key current concept: that the first change which occurs in cancer is an alteration of the hereditary material of a normal cell at the site where the cancerous process begins.

In the process of linking cancer to chromosomal material, Hansemann coined the terms "anaplasia" and "dedifferentiation." These terms have remained the basis of descriptive terms concerning the microscopical appearances of tumours ever since. Nevertheless, despite the popularity of his terminology, Hansemann's ideas were attacked vigorously by almost all proponents of rival theories of the nature of cancer. Partly due to these disputes during his life-time, and partly due to other factors, interest in von Hansemann's ideas diminished during the twentieth century and his works are rarely mentioned today.

This book presents translations of all the relevant German texts, and analyses the background and context of Hansemann's theories as well as the reasons why he was almost completely forgotten. It shows that some of Hansemanna (TM)s ideas may still be relevant to cancer research today, and that he deserves to be remembered in relation to cancer as Vordenker unter den fA1/4hrenden Denkern seiner Zeit - The foremost of the leading thinkers of his time.

Multivariate analysis is a mainstay of statistical tools in the analysis of biomedical data. It concerns with associating data matrices of n rows by p columns, with rows representing samples (or patients) and columns attributes of samples, to some response variables, e.g., patients outcome. Classically, the sample size n is much larger than p, the number of variables. The properties of statistical models have been mostly discussed under the assumption of fixed p and infinite n. The advance of biological sciences and technologies has revolutionized the process of investigations of cancer. The biomedical data collection has become more automatic and more extensive. We are in the era of p as a large fraction of n, and even much larger than n. Take proteomics as an example. Although proteomic techniques have been researched and developed for many decades to identify proteins or peptides uniquely associated with a given disease state, until recently this has been mostly a laborious process, carried out one protein at a time. The advent of high throughput proteome-wide technologies such as liquid chromatography-tandem mass spectroscopy make it possible to generate proteomic signatures that facilitate rapid development of new strategies for proteomics-based detection of disease. This poses new challenges and calls for scalable solutions to the analysis of such high dimensional data. In this volume, we will present the systematic and analytical approaches and strategies from both biostatistics and bioinformatics to the analysis of correlated and high-dimensional data.

Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the time of diagnosis. Patients are therefore often faced with a dreadful prognosis from a state of almost full physical health. Furthermore, because there is a high recurrence rate after curative resection, treatment of this tumor entity becomes a great challenge.

This book gives insight into the current understanding of the management of pancreatic cancer and considers recent findings in cancer research. It provides answers to questions of how to know when cancer is respectable, how to proceed when the diagnosis comes too late for a curative approach, and how to assess different study results. Moreover, it highlights new upcoming therapeutic options and experimental approaches, which might further improve the future prospects for patients with pancreatic adenocarcinoma.

Teddi Mervis lost her fight with cancer when she was 12 years old. Beginning with the diagnosis of her brain tumor, the story tells of her three-year battle for life--a struggle she eventually lost. Although Teddi passed away, her memory inspired those who had helped her to deal with her suffering to band together to aid other children who are facing cancer. These people and thousands of others inspired by Teddi's story--from construction workers to college students to bank presidents--helped form an organization whose primary purpose is to make the lives of children as happy and rewarding as possible. The organization, Camp Good Days and Special Times, Inc., has become one of the largest and most successful organizations of its kind in the world. It is credited with breaking down the barriers for children with cancer and creating pioneering new programs. The 2001 Edition carries the story forward from 1990 with new photographs and an afterword. This book serves to teach and guide those who must cope with the devastating ordeal of childhood cancer.

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

This book is based on presentations by some of the world 's leading experts at the Sixth International Conference on Clinical Cancer Prevention, held in St. Gallen, Switzerland, during March 2010. The main themes are the latest advances in the prevention of breast and prostate cancer and the role of infection in the development of liver and gastric cancer. Special emphasis is given to perspectives on the chemoprevention of breast cancer, as the conference included an international consensus meeting on this subject. New research findings are presented and potentially more effective cancer prevention strategies are discussed, with careful consideration of controversies. The expertise of the contributors encompasses genetics and microbiology, epidemiology, and health economics, as well as clinical cancer prevention. This book will be of interest to all who wish to learn about the most recent progress in combating the development of cancer.

Pancreatic cancer is a formidable disease, and advances in early detection and improved therapeutics have been slow to come forth. With new advances in molecular genetics in the field of pancreatic tumorigenesis, it is an opportune time to use these recent discoveries to enhance our understanding of pancreatic cancer biology and to improve outcomes in patients. In this volume, leading experts in the field shed light on these findings describing the mutational landscape of pancreatic cancer, including new inroads into our understanding of familial pancreatic cancer, epidemiology, the biology of K-ras signaling, and the emerging contribution of epigenetic alterations to disease initiation and progression. The distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation, hallmark mutations, EMT, and cancer stem cells is described, and implications of these interactions in the context of development of novel, personalized therapeutic options are explored.

Ovarian cancer is the most lethal malignancy of the female reproductive system and is also the fifth leading cause of cancer death in women. Sharing common characteristics of cancer, ovarian malignancy possess several clinical and biological particularities In "Ovarian Cancer: Methods and Protocols," expert researchers in the field provide methods that have been created or adapted to study various aspects of ovarian cancer. These methods and techniques are applicable to study genetic alterations present in ovarian cancer, structural and metabolic features of ovarian cancer cells, include in vitro and in vivo models that recapitulate ovarian cancer development and progression, and describe ovarian cancer-oriented drug delivery approaches. Methodological chapters are grouped into seven thematic parts, any of them is introduced by short subject review. Written in the highly successful "Methods in Molecular Biology" series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.

Authoritative and practical, " Ovarian Cancer: Methods and Protocols" seeks to aid scientist to optimize study designs, to correctly select the most applicable methods, and to produce interesting and novel results."

If there is one aspect of current cancer research that represents a major ch- lenge in both novice and experienced researchers, it is the rapid advance in our understanding of the disease. Researchers can be required to switch from analysis of gene expression to kinetics of protein activation, from genetic studies to the analysis of protein funtion. Cancers are highly complex disease systems and researchers aiming to understand the functioning of cancer systems require access to a wide range of laboratory techiques from a broad range of research disciplines. Increasingly, however, published methods are incomplete or refer back to a series of previous publications each containing only a small part of the complete pro- col. The aim of Ovarian Cancer: Methods and Protocols is to provide for ovarian cancer researchers in the first instance, a laboratory handbook that will facilitate research into cancer systems by providing a series of expert protocols, with proven efficacy, across a broad range of technical expertise. Thus, there are sections on tumor genetics and cellular signal transduction, as well as sections on apoptosis and RNA analysis. The value of Ovarian Cancer: Methods and Protocols to the ovarian cancer researcher will, I trust, be considerably enhanced by (1) the provision of a series of overviews relating to the biology, diagnosis, and treatment of this important neoplasm, and (2) the provision of a series of technical overviews introducing each part that provides an expert review of the applications and pitfalls of the various techniques included.

The goal of this work is summarize the contribution that insertional mutagenesis has made to our understanding of cancer. A variety of insertional mutagens are presented that have been used to study a variety of tumor types in several model organisms. In addition, the impact of insertional mutagenesis in several gene therapy trials is discussed along with strategies to avoid such complications in future clinical trials.